Denali Therapeutics Inc.
ANTI-APOE ANTIBODIES

Last updated:

Abstract:

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Status:
Application
Type:

Utility

Filling date:

27 Oct 2017

Issue date:

5 Sep 2019